What are your top takeaways in Breast Cancer from ASCO 2023?

1. SONIA: A notable trial comparing CDK4/6 inhibitors as 1st line vs. 2nd line treatment. AI+CDKi combination therapy as 1st line does not improve OS, 2nd PFS, or QOL compared to combination therapy as 2nd line. Factors such as the site of metastasis, tumor burden, symptoms, cost, and side effects sho...

1. NATALEE - Adjuvant Ribociclib study. Will be nice to be able to offer CDK4/6 inhibitors in high risk node negative patients as well as node positive.
2. SONIA trial - showed that there was no difference in benefit whether CDK4/6 is offered in first or second line was provocative
3. X-7/7 study - showed ...

The 2023 ASCO meeting did not contain much of general importance this year in my view, compared to last year's meeting. Only two abstracts stood out to me.

1. Abstract 503: Gray RG et al., Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis o...

NATALEE is important. However, the conclusion that ribociclib for 3 years in the high-risk adjuvant setting is similar to that of abemaciclib has limited impact. The median follow-up is too short given the length of treatment.